| Symbol | PHVS |
|---|---|
| Name | PHARVARIS N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | EMMY NOETHERWEG 2, LEIDEN, 2333 BK, Netherlands |
| Telephone | +31 712036410 |
| Fax | — |
| — | |
| Website | https://www.pharvaris.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001830487 |
| Description | Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Additional info from NASDAQ: |
Modig Berndt 🔴 sold 2.3K shares of Pharvaris N.V. (PHVS) at $34.77 Transaction Date: Aug 14, 2026 | Filing ID: 354965
Read moreNew Form SCHEDULE 13G/A - Pharvaris N.V. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000950142-26-002357 <b>Size:</b> 98 KB
Read more📋 Berndt B.A,E. Modig (Director) plans to sell 2K shares of PHARVARIS N V (at $34.04 each, total $78K) Filed: Aug 14, 2026 | ID: 008143
Read morePharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreAssessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
Read moreNew Form SCHEDULE 13G/A - Pharvaris N.V. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0001193125-26-326783 <b>Size:</b> 9 KB
Read morePublication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Read moreModig Berndt 🔴 sold 2.3K shares of Pharvaris N.V. (PHVS) at $34.97 Transaction Date: Jul 13, 2026 | Filing ID: 304445
Read morePharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Read moreLesage Anne 🟡 adjusted position in 4.6K shares (2 derivative) of Pharvaris N.V. (PHVS) at $35.12 Transaction Date: Jun 25, 2026 | Filing ID: 288863
Read more